Jaya Biosciences Completes Inaugural SCbioDrive Accelerator Program

November 22, 2024

We are proud to announce the successful completion of SCbioDrive, an accelerator program for emerging life sciences companies organized by SCbio in partnership with MassBio. JayaBio was one of seven oncology and neuroscience startups selected to be a part of the inaugural cohort.

Over the past eight weeks, JayaBio had the opportunity to connect with industry mentors, refine our strategies, and showcase our innovative approach to tackling neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and frontotemporal dementia.

“We were very impressed with the organization and quality of the SCbioDrive accelerator program. It has been an invaluable experience for our team, providing us with additional tools and insights to advance our mission of addressing unmet needs in neurodegenerative diseases,” said Pawel Krysiak, President and CEO of JayaBio.

“We are especially grateful for the guidance we received from leaders at Axonis, Eli Lilly and Sanofi. Their industry expertise and actionable insights will positively shape our approach to developing JB111 for PPT1-associated Alzheimer’s disease,” added Dr. Neal Goodwin, JayaBio’s Chief Scientific Officer.

During Demo Week, the inaugural cohort companies met with mentors and refined pitches in preparation for Demo Day, an end-of-program event where we presented our science to a diverse group of investors and other stakeholders.